An interventional study of adapted behavioral intervention in Schizophrenia, Schizo Affective Disorder and Schizophreniform Disorders, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 16 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Columbia University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Schizophrenia by Columbia University — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · Columbia University.
Among the 10 studies in Schizophrenia by Columbia University, this one is the 6th largest by enrollment, is one of 2 that started in 2024, is one of 10 with no phase, and was the 8th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 10 studies in Schizophrenia by Columbia University is open now, in 1 country. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–55
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 16 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2024.
This study's enrollment of 12 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 32 across the 10 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Schizophrenia by Columbia University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
The investigators will conduct an open pilot trial of a behavioral intervention to reduce violent behavior within the OnTrackNY network. The focus of this open pilot is to explore the acceptability and feasibility of the intervention. The study will enroll early intervention service (EIS) clinician - EIS participant dyads. The planned sample size is 3-4 EIS clinicians and 10-16 EIS participants (up to n=16 dyads). This real-world open pilot will provide feedback to help tailor the intervention to the OnTrackNY setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This will involve conducting a 12-week open pilot trial (up to n=16 dyads of EIS clinicians-EIS participants) to test the feasibility and acceptability of the adapted Psychological Interventions for Coping with Anger and Schizophrenia: a study of outcomes (PICASSO) intervention in the OnTrackNY setting.
Behavioral: adapted behavioral intervention
cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
Also known as: PICASSO
Mean Acceptability of Intervention Measure (AIM)
The AIM is a 5-item measure of the acceptability of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high acceptability.
Time frame: 12 weeks
Mean Feasibility of Intervention Measure (FIM)
The FIM is a 5-item measure of the feasibility of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high feasibility.
Time frame: 12 weeks
Number of EIS Client Participants in Attendance
The number of EIS client participants that attend the cognitive behavioral therapy sessions.
Time frame: 12 weeks
Seven clinician-client dyads (five clinicians and seven clients) were enrolled across participating OnTrackNY sites between March 2024 and June 2025. Three clinicians worked with one client each, and two clinicians worked with two clients each.
| Milestone | BRAVE Intervention - Clinician Participants | BRAVE Intervention - Client Participants |
|---|---|---|
| Started | 5 | 7 |
| Completed | 5 | 5 |
| Not completed | 0 | 2 |
The AIM is a 5-item measure of the acceptability of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high acceptability.
| score on a scale | BRAVE Intervention - Clinician Participants |
|---|---|
| Mean Acceptability of Intervention Measure (AIM) | 4.69 ± 0.65 |
The FIM is a 5-item measure of the feasibility of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high feasibility.
| score on a scale | BRAVE Intervention - Clinician Participants |
|---|---|
| Mean Feasibility of Intervention Measure (FIM) | 4.65 ± 0.65 |
The number of EIS client participants that attend the cognitive behavioral therapy sessions.
| Participants | BRAVE Intervention - Client Participants |
|---|---|
| Number of EIS Client Participants in Attendance | 7 |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BRAVE Intervention - Clinician Participants | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| BRAVE Intervention - Client Participants | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Age, Continuous(years) | BRAVE Intervention - Clinician Participants | BRAVE Intervention - Client Participants | Total |
|---|---|---|---|
| Mean | 34.2 ± 5.5 | 23.71 ± 2.3 | 28.08 ± 6.57 |
| Sex: Female, Male(Participants) | BRAVE Intervention - Clinician Participants | BRAVE Intervention - Client Participants | Total |
|---|---|---|---|
| Female | 4 | 1 | 5 |
| Male | 1 | 6 | 7 |
| Ethnicity (NIH/OMB)(Participants) | BRAVE Intervention - Clinician Participants | BRAVE Intervention - Client Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 5 | 4 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BRAVE Intervention - Clinician Participants | BRAVE Intervention - Client Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 4 | 4 | 8 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | BRAVE Intervention - Clinician Participants | BRAVE Intervention - Client Participants | Total |
|---|---|---|---|
| United States | 5 | 7 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Findings from this study will be presented to research peers, clinicians, and the public through Presentations at Scientific Meetings, Regional Research or Educational Meetings, Newsletters and Social Media and Peer-Reviewed Publications. Those events will occur during or at the conclusion of the study.
Time frame: Descriptive and raw data will be submitted on an annual basis. Unpublished de-identified data will be shared within one year after project completion, or when the data are published, whichever is earlier.
Access criteria: Data and materials will be made available for research to investigators working under a Federal Wide Assurance who meet security measures and data use agreement criteria associated with public repositories, including the National Database for Clinical Trials related to Mental Illness (NDCT) and the National Institute of Mental Health (NIMH) Database of Cognitive Training and Remediation Studies (DoCTRS).
Ran from Mar 2024 to primary completion in Oct 2025, 18 months.
Results were first posted in Oct 2026, 11 months after primary completion.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 18 months is below that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2026 → Oct 2025 and completion Aug 2026 → Oct 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.